Curative Biotechnology, Inc. OTC Markets

Equities

CUBT

US23128N1081

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
0.0164 ^USD	+12.33%		-6.29%	-23.00%

2021

Curative Biotechnology, Inc. Appoints Marc Drimer to Board of Directors as Independent Director and Chairman of Audit Committee

Connectyx Technologies Holdings Group, Inc. announced that it expects to receive $0.50 million in funding from Essential Strategic Partners Group, Inc.

January 14, 2013 at 04:00 am

Connectyx Technologies Holdings Group, Inc. (OTCPK:CTYX) announced that it intends to complete a private placement in its first round of funding for gross proceeds of $500,000 from a new investor Essential Strategic Partners Group, Inc on January 14, 2013.

Latest news about Curative Biotechnology, Inc.

Curative Biotechnology, Inc. Appoints Marc Drimer to Board of Directors as Independent Director and Chairman of Audit Committee

15/07/21

Chart Curative Biotechnology, Inc.

Duration

Period

More charts

Company Profile

Curative Biotechnology, Inc. is a development stage biomedical company focused on therapies for rare diseases. The Company is identifying, acquiring, and developing disease modifying therapeutic drug candidates with a concentration on rare disease indications. It has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro oncology. It is focused on its degenerative eye disease platform. The first therapeutic to be developed on this platform is a Metformin Reformulation targeting the treatment of intermediate and late-stage age-related macular degeneration (AMD) disease. Its pipeline products include IMT504, CURB906, Metformin Reformulation, and COVID Vaccine with IMT504 Adjuvant. IMT504 is an immunotherapy for late-stage symptomatic rabies. CURB906 is a humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor cancer site to kill the tumor by inhibiting tumor growth and migration of the tumor.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+23.11%	47.96B
IQVIA HOLDINGS INC.	+0.85%	42.45B
LONZA GROUP AG	+43.91%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+27.36%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.00%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.28%	14.56B
MEDPACE HOLDINGS, INC.	+44.81%	14.14B
BIO-TECHNE CORPORATION	+2.91%	12.58B

Other Biotechnology & Medical Research